LiverRight and Aegle Medical Solutions, LLC have announced a strategic partnership to expand access to non-invasive liver assessment, specialist interpretation, diagnosis, and ongoing liver care for patients across the United States. The collaboration brings together Aegle Medical's advanced liver assessment technology and implementation services with LiverRight's national virtual liver clinic, creating a more connected pathway from liver disease identification to specialist review and longitudinal management.
For physicians, health systems, and independent practices, the partnership is designed to simplify the establishment or expansion of comprehensive liver disease programs without having to build every component internally. Aegle Medical provides a consultative approach to technology evaluation, implementation, clinical training, and ongoing support, including the Mindray Hepatus-Series Transient Elastography Diagnostic Ultrasound Systems. LiverRight offers same-day interpretation services for liver elastography studies and same-week virtual access to its hepatology clinicians. Its Liververse™ referral system coordinates bloodwork, patient-reported outcomes, available imaging, diagnosis, and longitudinal disease management.
The partnership addresses a critical gap in liver care: a significant number of adults in the United States live with undiagnosed liver disease. By bringing advanced liver assessment into the outpatient setting and providing timely specialist interpretation, the collaboration aims to move patients more efficiently into appropriate diagnostic and care workflows. "Aegle Medical Solutions is helping hospital systems and independent practices nationwide address the significant number of adults living with undiagnosed liver disease in the United States," said Brandon Tudor, CEO of LiverRight. "By working together, we help practices bring advanced liver assessment into the outpatient setting, provide timely specialist interpretation, and move patients into the appropriate diagnostic and care workflow with greater efficiency."
Michael McTighe, President & CEO of Aegle Medical Solutions, emphasized the broader impact: "This strategic partnership with LiverRight represents an important step forward in our shared vision of expanding access to liver disease detection and care within the communities we serve." He added that the model can be particularly valuable in communities with limited access to hepatology specialists, helping providers identify liver disease earlier and improve patient and clinician experience.
A key technological driver is the Mindray Hepatus platform, which introduces Visualized Transient Elastography (ViTE). This next-generation technology integrates real-time B-mode ultrasound visualization directly into the elastography examination, allowing operators to see liver anatomy, identify optimal measurement locations, and visually guide each acquisition while obtaining quantitative liver stiffness and attenuation measurements. Unlike legacy platforms that may require different probes based on patient body habitus, the Hepatus is designed for a more efficient, b-mode image-guided workflow. It provides liver stiffness measurement (LSM) for fibrosis assessment and Liver UltraSound Attenuation (LiSA) for quantitative assessment of hepatic steatosis. The Hepatus 6 further expands capabilities with diagnostic ultrasound imaging, supporting abdominal imaging, Doppler, spleen stiffness assessment, and intestinal ultrasound.
LiverRight's hepatologists and advanced practice providers are licensed across all 50 U.S. states, supporting adult patients with conditions including MASLD/MASH, alcohol-associated liver disease, hepatitis B and C, primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis, and liver cancer diagnosis. The partnership offers a scalable approach that can operate under the provider's brand, combining technology, implementation support, specialist interpretation, and continued liver care. This collaboration matters because it directly tackles barriers to timely liver disease diagnosis and treatment, potentially improving outcomes and reducing total cost of care by making advanced assessment and specialist expertise more accessible.
